clinical trial · NCT06281964
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Avistone Biotechnology Co., Ltd.·phase3·enrolling by invitation·n = 327
Non-Small-Cell Lung CancerPLB1004Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab
brief summary
Efficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.
started
Dec 1, 2023
primary completion
Jun 30, 2028
completion
Jun 30, 2030
last updated
Apr 23, 2026
detailed description
Randomized, controlled, open label, multicenter phase III study to evaluate the efficacy and safety of PLB1004 Versus platinum-based chemotherapy with or without Sintilimab in the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 insertion(ex 20) mutations.
official title
Randomized, Controlled, Open Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of PLB1004 Versus Platinum-based Chemotherapy With or Without Sintilimab of Advanced NSCLC With EGFR Exon 20 Ins Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol